<SEC-DOCUMENT>0001193125-14-419150.txt : 20141120
<SEC-HEADER>0001193125-14-419150.hdr.sgml : 20141120
<ACCEPTANCE-DATETIME>20141120070232
ACCESSION NUMBER:		0001193125-14-419150
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141120
FILED AS OF DATE:		20141120
DATE AS OF CHANGE:		20141120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		141237432

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d824795d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 20 November 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g824795g44y70.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Shares on issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">185 M</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of
Directors</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman &amp; Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 20, 2014</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN ANNOUNCES IDENTIFICATION OF LEAD ATM DRUG CANDIDATE</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen today announced that it has identified its lead anti-tropomyosin (ATM) drug
candidate. This follows the announcement on 12 November at the 2014 Annual General Meeting that the Company had refined its search to 5 candidate compounds with the final selection imminent. The final selection was confirmed yesterday with the
Company confident that it has developed a major new initiative in the field of chemotherapy.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The main clinical application of ATM-3507 is believed to lie in its ability to significantly boost the anti-cancer activity of certain existing chemotherapies
and to do so in a safer way.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Those existing chemotherapies come from two classes of
drugs known as taxanes and vinca alkaloids. Together these drugs are among the most widely prescribed drugs in oncology, serving as first-line therapies for cancers such as breast, prostate, ovary, lung, head and neck and a range of hematological
cancers.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The taxanes and the vinca alkaloids target the skeletal structure of the
cancer cells, known as the cytoskeleton. This cytoskeleton is vital to a cell&#146;s ability to divide and to survive and it has two main components &#150; the microtubules and the microfilaments. The taxanes and the vinca alkaloids target the
microtubules, in so doing blocking the cancer cell&#146;s ability to divide and ultimately to survive.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Justine Stehn, Novogen ATM Program Director, explained, &#147;The microtubule inhibitors have been the backbone of chemotherapy for the past 40 years, but
they come with three main problems. One is that they are toxic because their inhibitory effect is not limited to cancer cells. Another is that cancer cells rapidly develop resistance to these drugs. A third is that many forms of cancer show no
response to these drugs.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The strategy we adopted 8 years ago was to find a
way of knocking out the other main component of the cancer cell&#146;s cytoskeleton, the microfilaments. The reasoning was that by comprehensively knocking out both parts of the cytoskeleton, that the anti-cancer effect would be considerably
enhanced.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to see that this is the case. ATM-3507
significantly increases the sensitivity of cancer cells to the microtubule inhibitors, resulting in much enhanced cancer cell killing with significantly lower amounts of drugs, an important step-forward in potentially reducing the toxic side-effects
of those commonly-used chemotherapies. Novogen is in the unique position with ATM-3507 of having the potential to improve the effectiveness and safety of these very common standard-of-care drugs,&#148; Stehn added.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page&nbsp;&nbsp;|&nbsp;&nbsp;<B>2</B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ATM-3507 was designed by a team of Novogen chemists led by Dr Andrew Heaton, Novogen Vice-President of Drug
Discovery and Manufacture. ATM-3507 targets the terminal end of the Tm5NM1 tropomyosin isoform, a form of tropomyosin that is prevalent in cancer cell&#146;s microfilaments. In the laboratory, ATM-3507 has proved to be highly effective in disabling
the microfilaments of cancer cells, resulting in their death. This has been observed across a broad range of cancer types, although the focus has been on prostate cancer and melanoma and the main solid cancer of children, neuroblastoma. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen now is looking to bring ATM-3507 into the clinic in combination with taxanes or vinca alkaloids in the treatment of prostate cancer, melanoma and
neuroblastoma with a target of being in a first-in-man study by early-2016. The studies preparing ATM-3507 for entry into the clinic are ongoing in Australian and US hospitals and universities. The development of ATM-3507 comes under the broad
umbrella of The Children&#146;s Oncology Drug Alliance (CODA) involving The Kids&#146; Cancer Project (Sydney), The University of New South Wales (Sydney), The Nationwide Children&#146;s Hospital (Columbus, Ohio), and Novogen. Novogen owns all
intellectual property in relation to ATM-3507. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Peter Gunning, Non-Executive Director of Novogen, and inventor of the ATM drug technology, said,
&#147;The original impetus for the ATM drug technology was the need to find more effective and safer therapies for pediatric cancers. Walking through the cancer ward in a children&#146;s hospital is a powerful incentive to improve the health of
children with cancer. To finally have the drug that we are confident of taking into the clinic brings this dream within sight.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ATM-3507 has been
given the name <I>Anisina</I>, Turkish word for &#145;in memory of&#146;, in memory of the children whose deaths were the stimulus that led to the development of this technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian
drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ (&#145;NVGN&#146;). The Novogen Group includes a New Haven CT &#150; based joint venture company, CanTx Inc., with Yale University.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full
range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal
destruction of the cancer cell&#146;s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the
ultimate objective of employing both technologies as a unified approach to first-line therapy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on our websites
<U>www.novogen.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Graham Kelly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chairman &amp; CEO Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4100</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cristyn Humphreys</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operations Manager Novogen Group<BR><U>Cristyn.Humphreys@novogen.com</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4111</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g824795g03v55.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g824795g03v55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g824795g03v55.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"``S`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]0;K4I8+AT18R%Z9!_P`:A_M>;^[%^1_QJ+4/^/R7ZC^55J`+W]KS
M?W8OR/\`C1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO
M-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_
M=B_(_P"-']KS?W8OR/\`C5&EH`N_VO-_=B_(_P"-']KS?W8OR/\`C7+ZEXGB
ML9VAAB:=T.'.=H!]/>LN7Q9>/D1I!&#T^4DC]:KD9A+$TXZ7.\_M>;^[%^1_
MQH;6944LPA`'<@_XUYO-KE_.H#W,@Q_<PG\L52E=IF+2LSL1]YCD_G5>S,98
MU=$=Y/X]CMQEY[$C.,)EB/P!JE+\4(X_N(LOH4C.#^;"O.71D/S@BFTU!&,L
M9-[([N;XK71!%O96X/8NQ/Z`_P!:K_\`"U-5_P"?;3_^_;__`!5<913Y49O$
M57U.S_X6IJO_`#[Z?_W[?_XJC_A:FJ_\^^G_`/?M_P#XJN,HI\J%[>IW.S_X
M6IJO_/OI_P#W[?\`^*H_X6IJO_/OI_\`W[?_`.*KC**.5![>IW.S_P"%J:K_
M`,^^G_\`?M__`(JC_A:FJ_\`/OI__?M__BJXRBCE0>WJ=SL_^%J:K_S[Z?\`
M]^W_`/BJ='\5=3##S;6Q9>X57!_/<:XJBCE0>WJ=ST"'XK2-_P`?%FB?[F6_
MF15V+XE02XR\,9/9XG'ZYKS*BDX(T6+J+?4]:B\9F=ML$EC(?16R?YU/_P`)
M+<_W+?\`[Y/^->/5-#>7%NN()Y8QZ*Y`J?9FL<;W1ZW_`,)+=?\`/.#_`+Y/
M^-'_``DMU_SS@_[Y/^->9P^)M0A(S,L@`Z/&#_+FKD/C*8$_:;:-_0QL5_QI
M<C-HXNFST#_A);K_`)YP?]\G_&C_`(26Z_YYP?\`?)_QKGM-U.'5(2]ON&T@
M,K#!!JW4/0Z(R4E=&M_PDMU_SS@_[Y/^-'_"2W7_`#S@_P"^3_C6310,UO\`
MA);K_GG!_P!\G_&I[77KB?=O2$;1V!_QK"J[8HR!RPQD<4`:W]KS?W8OR/\`
MC1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_X
MT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_P"-
M']KS?W8OR/\`C5&B@"]_:\W]V+\C_C1_:\W]V+\C_C5&B@"ZVM2H,LL>/8'_
M`!J,^().R1G\#_C5*X_U?XU6H`TSX@N.R0C\#_C1_P`)!<?W(?\`OD_XUF44
M`:?_``D%Q_<A_P"^3_C1_P`)!<?W(?\`OD_XUF4$XH`T_P#A(+C^Y#_WR?\`
M&C_A(+C^Y#_WR?\`&LK=1N-`%'5_B'J-AJ,D$,%DR(%P61B>0#_>JH/B;JS'
M"6UBQ]!$Y_\`9J@U2)'OY&=$+<<E1Z5"`!TK6R['`_:<S]XN3>/O$TO-G!I4
M8QTFM9#_`.U151_'?C=&)$/AAHQZ13[ORWX_6DI#T/T_K3NNQ,HR?VG]Y'!\
M6-?4YN8]'<>B6TBX_$RFIO\`A;6L?\^VF_\`?M__`(NN)_A%%:\D>QP/$UD[
M<S.V_P"%M:Q_S[:;_P!^W_\`BZ/^%M:Q_P`^VF_]^W_^+KB:*.2/87UJM_,=
MM_PMK6/^?;3?^_;_`/Q='_"VM8_Y]M-_[]O_`/%UQ-%')'L'UJM_,=M_PMK6
M/^?;3?\`OV__`,71_P`+:UC_`)]M-_[]O_\`%UQ-%')'L'UJM_,=M_PMK6/^
M?;3?^_;_`/Q=0S_%C7F(^S1:0@QSOMI&_E(*X^BCDCV#ZS6_F.BF^+?C!#^X
MMO#DB^\,RG_T9_6J,_QL\;6XR^CZ,1G'R0R/_*6LNBJ2CV,G5KO:HT32_M#^
M*H'VSZ;HT;?W7MYE/ZR5'_PT?XE_Y\=#_P"_,O\`\<IO48/0]:IS:/8S@B6T
M@Y.253:?S%4E3ZQ,7/&=*K+W_#1_B7_GQT/_`+\R_P#QRN@T3XJ>/=>MH[FR
MTG0!:RYVS2*X!P<'CS<]0>W:N#F\(Z?*1L$T/^X^?YYKT?P78)8>&[6UADWK
M&7))ZC+DX/YTJGLTKQ1O@EBZE6U6H[>3-FS\5^,''^GOX:A.>D-K/+_.1:U[
M?Q;J*Q*+H64DO=HX60'\"Y_G62R%>OYTVN9V9[\(<O5OU.A@\4W<N[=';C`[
M*?\`&K(\17&>8X2/H?\`&N>L_P"/Z5<K-[FJ-<>(I?XHX_P!_P`:D37G<X"I
MGW4_XUB5)!_K5^M(9M?VO-_=B_(_XT?VO-_=B_(_XU1HH`T8=5EDF1&6/#,`
M<`^OUK4KG[7_`(^8?^NB_P`ZZ`=*`,/4/^/R7ZC^55JLZA_Q^2_4?RJM0`44
M44`%%%%`!3)YXK:,R7,L<4:]7=@H'U)I]<%\8<?V/8_]?)_]!-5&/,TC'$U?
M94G4['0WGCC0;''G:I;-G_GB3+_Z`#6+=_%K2(=PM8KRX8?=(0*I_$G(_*O(
M*/Z5U*A%'S\\YKOX4D>C7'QCE8$6FEQH>QDG+?H`/YU8MOC)&7`O-+=%[M%/
MN/Y$#^=>:102S_ZB.23_`'%)JY'H5[*JD0E0W]X@8_#K3=*'8RCF&->S_!?Y
M'07OQ*T2XU.Y,KW-MF1C^]A)_P#0<U;M?$VDWH3[-J%HQ?A5,H5C_P`!/->>
M77@BYGOIGGGAB5G)&T%C^7%3VW@6V3_CXN9I,'^`!!_6K<*=MR(XC%-MN*_(
M]/!!Z'-%3:3IMO;:3911HQ6*!%7+'H%%6_LL7]S]37.VCUHT)-)F:5!Z@4QK
M>-NJ+^`Q6D;*,]"P_&HS8'^%Q^(I70.C-&:UC&>A(J(Z>>S@_A6H;.4=`&^A
M_P`:C,3KG<C#'M3,W%K=&8;*4=@?H:B:&1>J-Q[5J@@G@YHQ0(Q\T5KE%;[R
M@_45&UK$W\(!]J`,RBK[6"'[K$5$U@X/RL#^E`%6BIC:2C^'/T--\B3_`)YO
M_P!\F@".BI!;RGI&WXC%2+92'J`OU-`%>BKBZ?\`WG_(5(+&,=<GZT`9]*%)
MZ`GZ"M18(T'RHOY4\#'2@#6\&6TK6]R0A`\Q>3QV/^-=*MDY^\5'ZUF^#O\`
MCVN_^NB_RKH#UK&:LSU\-_"15%BO\3D_08J06L0_A)^IJ6BI-A%14^XJK]!2
MT44`%%%%`!1110`4444`%%%%`!1110`4444`-E4NF%ZU6:-EZJ?PYJW2T`4<
M45=(!ZC--,2-U44`5*1_O&K1MU[9%0/"0YYH`BHI_E-[4OD\<F@#G]2_X_9/
MP_E5:J'BG4[BUU>>&`JBJ%(;;DGY16%)J5S)]^:3GKAL#\A70H71Y57$QC-H
MZJ21(EW2,J+ZL<"JL^JVL(.Z96..`GS9_*N6)W')Y-%5[,PEBV]D'844459R
M-W84444""BBB@`HHHH`****`"BBB@`HHHH`*56*'*D@CH0:2B@+B:MXBU+3M
M+N)K2\F61%&TN=^.1V;(KG[/XL:Y;*!/]CN^>6EAP?\`QT@?I5_Q'_R!+K_=
M'_H0KSZMZ<(R6J.'%8JO2J+DFT>]_#GQB?&<][&UJ+0VRIR)=^[<3VP,=*[X
M6J+][+?C7CWP"4_;-7;!VA8<G'NU>S&N"O%1J-(^FRRM.KAHSF[O7\Q@AC'1
M!^/-.`QTHHK(]`****`);7_CYA_ZZ+_.N@'2N?M?^/F'_KHO\ZZ`=*`,/4/^
M/R7ZC^55JN7T$KW<A2.1@2,$*?2H/LLW_/&7_O@T`145+]EF_P">4O\`WP:;
M);3\;89>G.$-`##QUI"ZCO2?8[C_`)X3?]\&C['/_P`\)O\`O@T`'FCWJEJ6
MGVFKPB+4K:*XC4Y`D&=I]0>H/TJ[]CG_`.>$W_?!H^QS_P#/";_O@T)V%)*2
ML]CDIOAMH,AREK)%_N3N?YDU%_PKNSB(^RNB;?NEH0S#\<UV7V.?_GA-_P!\
M&C['/_SPF_[X-7[27<Y_JE#^1'$2>$+Q/]6T#@>C$?TJ2'P=<N?W\T,8_P!G
M+'^E=G]CG_YX3?\`?!H%G/\`\\)O^^#1[20+"4TSSNX\*0QW,HGFED(;'R@+
M_C4D>@V,>,0[B.[,3FNLOO#UU+*TD,<AW')4QD52?0=03K:3D>R$U?.V9?5X
M1?PF>`%4!0%4#``&`*6K?]CW_P#SY7?_`'Y;_"C^Q[__`)\KO_ORW^%*Z+L5
M**M_V/?_`//E=_\`?EO\*/['O_\`GRN_^_+?X470[,J45;_L>_\`^?*[_P"_
M+?X4?V/?_P#/E=_]^6_PHNA6*;*'^^`WU&:C:UB/\`!]N*T/['O_`/GRN_\`
MORW^%']CW_\`SY7?_?EO\*+B<$]T9;6*'[K,OUYJ-K%A]UE/UXK8_L>__P"?
M*[_[\M_A1_8]_P#\^5W_`-^6_P`*?,0Z$7T,1K65?X<_0U$59?O*R_48KH/[
M(O\`_GRN_P#ORW^%']D7_P#SY7?_`'Y;_"CF,WAET.>HZ=*W9-!NY`=UA=9P
M<$0,#_*L\:'J6/\`D'WW_@.W^%.Z,9TI1=BE15[^P]2_Z!]]_P"`[?X4?V'J
M7_0/OO\`P';_``IJQ'++L4:*K:Y%KNFR(ECX?U.\WJ262VD(4^^%KGKB3QK,
M"(M`U.#T*:9+D?F#6BIM]3&=51=K/[CJJ*Y&"/QPK_-H^K29Z!],<#]%%;VE
MVWBJXFCCO_#US$'<*9/*D4*">O1J3A;J*%7F^R_N.Y\'?\>UW_UT7^5=`>M5
M-&T"72H'0K+(TK!F/ED`<=*O_99O^>4O_?!KFF[L]ZC%QII,BHJ7[+-_SQE_
M[X-'V6;_`)XR_P#?!J34BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BI?LLW_`#QE
M_P"^#1]EF_YXR_\`?!H`BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BBX#VR;Y8;D
MC_IG;O(?R4$UF7.MO"<0Z5K=QQG,=@X'_CP%-)LB52,=V:=%<S-XEUGYA;^&
MM1]B\4A_0+_6J]K=^*=49Q);3Z<$P05TYCN_[ZS5>S=KLQ^M0YK)-_+_`#.N
MJM/,D))F=4'JQQ6!)H6J3DM=2:U+N'S*"R(?P4"I+?PNT<>V.QNT&23E7//X
MT<J[E*I-_9-"36+.(X:=3_N@M_*HQKUD?^6C#_@!_P`*IOX6N#DQPW0]C$36
M<=#U')_T"]X/_/!O\*?+%D2JU(O5&U=-I6K)MNS;R@="_P`I'T/!_*J,W@K2
M[CYH#+"O_3.7(/YYJG_8FI?\^%[_`-^&_P`*5=&U-&#)8WRD=Q`P_I5;;,RE
M.,OBA<BF^'_RDVUYD]@\7]<_TK-N/!&I0#*+#/[1R8_GBNACAUR(Y2WU$_[T
M+-_,59BFUM,!]/N9/=K9A_*FI21#HT)?9:.$GT/4+<D2V=QP.2L98#\1Q5(J
M0<8->IQWE_N_>Z3?J.^V)C_2I6C^VIMN]-NRHZ++9LP_D::J/JC-X&#^&1Y-
M17J<O@ZRNQN;370GILC>/'X#%9T_PUA=2;?[;$W;*;A^6,_K356)G++ZJVU/
M/:*[&?X9WRX^S2>9SSYD+)C\LUG7'@/7(2=EA)*J_P`2$<_@>?TJE.+ZF$L-
M6CO$Y^BM+_A&=7'_`#"]1_\``5_\*/\`A&M7_P"@7J/_`("O_A3NC/V<^QFT
M5IIX7UB1PJZ7J&2>]LZC\R,5OZ-X(OD$C:CISALC9O7<,?09I.22+IX><Y6L
M<<%)Z#)]*L1Z9=2D!+>7GH2N!^9KT:#PQ-$N%A>,'JJ0$5870)!U@N6^J&H=
M5';'+WU9YY%X<NY!E_+C_P!YO\,U;B\*EB-\_/=53_Z]=ZNCNO2TE_&,FI!8
M7"C"VTP'H(S4.JS>.!IK<XZ#PG`#S%-)Q_&VW_"ISX-MY!C9Y6>XD)/ZYKJ_
ML-S_`,^\_P#W[-'V&Y_Y]Y_^_9J?:2-OJM+L<5=_#FTOH7@N;JY$$@PPCVAN
MN>"01V]*73_A)X5M$Q<6MU=MG.Z>X;_V3:/TKM/L-S_S[S_]^S1]AN?^?>?_
M`+]FFJLUU(^HX:]W!-^>HFG6=EI=LMOID-O:PKR$B0(,^N/7CK5H$-]TY^E5
MOL-S_P`^\_\`W[-'V*Y'2WG_`._9K,ZDDE9%FBF0VUT'&Z*?!ZY0U8^RS?\`
M/&7_`+X-`R*BI?LLW_/&7_O@T?99O^>,O_?!H`+7_CYA_P"NB_SKH!TK#MK>
M5;B(M%(`'&24/K6X*`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
0B@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g824795g44y70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g824795g44y70.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"4`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]1;G4OL\S1^7NQCG=C^E1?VS_`-,1_P!]_P#UJK:G_P`?C_0?RJK0
M!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_Z8C_`+[_
M`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS_P!,1_WW
M_P#6H_MG_IB/^^__`*U9E%`&G_;/_3$?]]__`%J/[9_Z8C_OO_ZU9E%`&G_;
M/_3$?]]__6H_MG_IB/\`OO\`^M6910!I_P!L_P#3$?\`??\`]:C^V?\`IB/^
M^_\`ZU9E*,9%`%AO$^&(^S=#_P`]?_K4G_"4?].P_P"_O_UJYR_OH+!6>ZD5
M,Y*@GEOH*Y;4_%$UR"ED&@C/4Y^8_P"%5&-S&K7A#=ZG>ZE\0[;3%(EMR\N,
MB-)<G\>.*RA\601D:5_Y-?\`V->>$DDDDDGKFDK3D1PSQ<V_=T/1?^%L_P#4
M*_\`)K_["C_A;/\`U"O_`":_^PKSJBCD1'UFKW_(]%_X6S_U"O\`R:_^PH_X
M6S_U"O\`R:_^PKSJBCD0?6:O?\CT7_A;/_4*_P#)K_["C_A;/_4*_P#)K_["
MO.J*.1!]9J]_R/1?^%L_]0K_`,FO_L*5/BPA=1+IC*A/)6XW$?AMKSFBCD0U
MB:O<]BM?&<-['OMH5=>^)>GZ5-_PE'_3L/\`O[_]:O';:ZFM)`]M(T;CNIZ_
M7UKI--\5(X6/40$;IYB_=/U]*B4+;'72Q49:2T9WW_"4?].P_P"_O_UJ/^$H
M_P"G8?\`?W_ZU8,;K*@>)E9&'!!SFEJ#KZ7-W_A*/^G8?]_?_K4?\)1_T[#_
M`+^__6K"HH`W?^$H_P"G8?\`?W_ZU'_"4?\`3L/^_O\`]:L*B@#=_P"$H_Z=
MA_W]_P#K4?\`"4?].P_[^_\`UJPJ*`-W_A*/^G8?]_?_`*U36_B#SRW^C[=H
M_P">F?Z5SE6]/ZR?04`;O]L_],1_WW_]:C^V?^F(_P"^_P#ZU9E%`&G_`&S_
M`-,1_P!]_P#UJ/[9_P"F(_[[_P#K5F44`:?]L_\`3$?]]_\`UJ/[9_Z8C_OO
M_P"M6910!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_
MZ8C_`+[_`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS
M_P!,1_WW_P#6I#K849:(#_@?_P!:LN1_+7(&:K/(7.6H`V#XB':#/_`__K4?
M\)%_T[_^1/\`ZU8M%`&U_P`)%_T[_P#D3_ZU'_"1?].__D3_`.M6+10!M?\`
M"1?]._\`Y$_^M1_PD7_3O_Y$_P#K5BT>M`#-2^)']G7LMN=.\SR\?-]HQG(!
MZ;?>JW_"UO\`J%G_`,"O_L:Y3Q+_`,ANY_X!_P"@BLL^O:MHQ6AYE3$5%-I,
MZW5OC-=Z<IDM_#OVN(#+%-0PR_5?+_E6`/VE\D`>&R23@#^T>_\`W[J*VL);
MC!`")ZFEN/"]B-]Q#!&MV%XE"@%C5KV2T:.:I+&O6%2R]%_D=#I_QKN;N/?<
M^'OLJD94-J&6/U'EC%6_^%P_]0C_`,G/_L*\X)Z4E-TX=B%C*Z5G+\%_D>D?
M\+B_ZA/_`)-__84?\+B_ZA/_`)-__85YO11[.(_KM?\`F_(](_X7%_U"?_)O
M_P"PH_X7%_U"?_)O_P"PKS>BCV<0^NU_YOR/2/\`A<7_`%"?_)O_`.PH_P"%
MQ?\`4)_\F_\`["O-Z*/9Q#Z[7_F_(](_X7%_U"?_`";_`/L*HZC\;KJR7?!X
M<-S&!\VV_P`,/P\O^M<+2AJ:IP6Z%+%UVM)V^2_R-\?M,#OX<(_[B/\`]KH_
MX:87_H7?_*C_`/:JXS5/#]KJ8+%1%,>DBCK]1WKD=3\/76F$ET\R(?\`+1.G
MX^E;0I4I=#SJN.S"GKSW7HO\CV'_`(:87_H7?_*C_P#:J/\`AIA?^A=_\J/_
M`-JKPS'%&*OZM2['/_;&-_G_``7^1[G_`,-,+_T+O_E1_P#M5+_PTPO_`$+O
M_E1_^UUX7BN^\%_#@:M;0ZAK#LMK+\R01\,Z^I/8?3FIG1HQ5VC?#X_,:\^6
MG*[]%_D>A:3\?[W6[GR-,\*23-_$?[1PJCU)\K`%=U;^-9'A4W-@D<I'S(ES
MO`_':/Y5RUCI]MIELL&GP1P0KT5%Q^?K4]<<^1_"K'TV'A7BOWL[OT2.JB\6
M>:#_`*+C'_37_P"M4R^)03AK<J/7S,_TKF;3HWX5;K)[G4MCHAK8896($?[_
M`/\`6I?[9_Z8C_OO_P"M7.JQ1LJ<&K4-QYAVL,-_.D,V/[9_Z8C_`+[_`/K4
M?VS_`-,1_P!]_P#UJS**`-:#53/,J>5MW'&=^?Z5H5@V/_'W%_O5O4`8>I_\
M?C_0?RJK5K4_^/Q_H/Y55H`****`"BBB@`HHHH`****`"BBB@`I0,TG0<]JQ
M]3\3P6>4M?W\HZ[?NC\>]-)LF4HQ6KL:TLL<$9>9U1!U9C@5SNJ>*PKE-+&[
MG'FL/Y#_`!K"O-0N-1?==R,P!X4<*/H*@QCI6B@CSZV+E+2.B,RYN9+N9I+E
MVD<D\L<U%2GJ?K25?2QR!1110`4444`%%%%`!1110`4444`%%%%`BY8ZK<Z>
M3]GE(4]48Y!_"NIT[Q';7VU)3Y,Q_A)^4_0UQ5`XS[U+BF;TJ\H:'I=%<3IO
MB*YL"$D8SQ=-C'D#V/\`C75:?JUMJ2`V[X?',;<,*AP:/1IUX36^I<HHHJ#8
M****`"K>G]9/H*J5;T_K)]!0!:HHHH`****`"BBB@`HHHH`****`"BBB@!ES
M_JQ56K5S_JQ56@`HHHH`****`"@#)XHIK-@\4`<=K]N]QK=P(@3]S)QP/E%)
M;Z:D6#+\[>O85JZC_P`?LA/?'\A5:MNAYSI+F;`<#`IDOW&_W33Z9+]QO]TT
M%2V..-)2M25NMCQY;A1110(****`"BBB@`HHHH`*&PP(8`@]11136@&%JGA.
MWO`9+'_1YO3/R-^':N2O=.N-/EV7<;(W8GH?H:]*ID]O%=1&.XC1T/4,,U<*
MC3U.6KA(SU6C/+Z]]\%?\BII7_7LM>5ZIX-*AI-,?/<Q.?Y'_&O5O!T;1>&-
M-212K);JK`CH:6(:<4S?):,Z>(ES=OU-FBBBN0^H+5IT;\*MU4M.C?A5NLWN
M4M@J6V_UP^A_E452VW^N'T/\J0RW1110!8L?^/N+_>K>K!L?^/N+_>K>H`P]
M3_X_'^@_E56K6I_\?C_0?RJK0`4444`%%%%`!1110`4444`%+24HZT`<SXKU
M1PPL[<E1MW2D'KZ"N;"@=!6AXA_Y#MR!TPO_`*"*H5NMCQZ\W*;N%!.!D]J*
M#R#3,C(8;68'J#25<N;8G+)][J1ZU4((ZT`)1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4Z.1HI`T;%64Y!'44VC&:!IV9WFB:E_:=BLCX\Q?E?'J/\`
M]=7ZYWP;Q#=#MN7_`-FKHJPEN>Q0ES4TP_$#ZFN0OOC#X"TR\GM-1\<>#[2Z
MMI6BG@GURVC>)U.&5E+Y!!!!!Y%97[0?C^]^&/P=\3>(]%@DGO[*V5+9E7<(
M))'6-9B/1"X<_P"[VZU^2$LTD\KRW#O)+(Q9W=LLS'J2>YS7#B\7[%I)79]W
MPKP@LWHSK5:CC%.RM;5[L_:RQOK;5+*"\TV>&ZM+J-98)X)`\<J,,JRL.""#
MD$<5I6`P9"?3%?)'_!/[XBW^O_#G6/#VMB3[+X4N(_LE[*0$$4^YO)+$]596
M/LKJ.,"OK:TO;-R(K:[MYI#D[4E5B?P%=5*I[2FIVW/E\XP7]G8^IA)R5XO[
MUNOO5BW1115G`%%%%`!1110`4444`%%%%`!1110`RY_U8JK5JY_U8JK0`444
M4`%(3BE'6FMUH`0\G-!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>
M["F2_<;_`'33Z9+]QO\`=--$RV..:DI6I*W6QX\MPHHHH$%%%%`!1110`444
M4`%%%%`!1110`HKOM$&_2+;=S\@K@5ZUUOA[7(#;16MPPAD0;5+'AN>*BHKH
M[L%)*;N;+*5//3L:;4LH^7Z5%61ZY:M.C?A5NJEIT;\*MUF]REL%2VW^N'T/
M\JBS5BWB((=ACT%(98HHHH`L6/\`Q]Q?[U;U8-C_`,?<7^]6]0!AZG_Q^/\`
M0?RJK5K4_P#C\?Z#^55:`"BBB@`HHHH`****`"BE^E<]XC\;Z9X=0K/+Y]UV
MMXF!;_@1Z+347+1$5*D*<>:;LCH.N,<YZ4HZUX7K_CS5M>D(:<VMMGY88&*C
M\3G)_E[5=\.?$G4='V0WV[4+4'[KM^\0?[+=_H<UM]7E8\Y9O0YK.]NYUOB+
M_D/77T7_`-!%4*9-XCL?$.J7$VFS!C\H:)OE=?E'53SCWI]5RM+4PG.,I.47
M=!1112)#&:BFMEE'0`^HJ6B@#-FMVB'(R/45#FM=ER#[U7ELU;++P>X]:`*%
M%/>)HSAQBF4`%%%%`!1110`4444`%%%%`!1110`4444`=3X-_P!3<_[R_P#L
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MX&^-`I`/3`3/S*:\^\#>,K_X?>+--U_1&VW6FS"3;T$J='C/LRD@_6NI\/Z2
M_P`0?AW<V<]S:6=UX0G22RO;Z800FVN7.^W,C?+N$N)$!_O3>E3^#OA?!'K8
MO/$&HZ!JVG:7;S7]SI^F:M%//=K!&TGE*JG.&V88CHNX]J]_#TZ.&H>QZ1T]
M3\8SG&9EG6:O,FVY5&I)]O+Y-?J??-C\5?"EWI]E=7>OZ/IK7UK%<K;7M_%#
M-&LB*ZAT9@P.&'&*Z+3=5LM9L4O=(N[6^LY03'<6TRR1O@X.&4D'!!'7M7Y3
M:_KMYXFUN]U75I/,O+^=I9F`P,D]%'8`8`'8`#M7U%^Q!\0KUGUOP;=I-/9+
M;OJ%I*!D6Q!"R*3V#%E(]P?6O+Q64>RHNI&6W3^NQ]OD?';QV/CA*M.REHI*
M^_2ZZ7_`^L](UO3O$%I]JT#4++4[7<4\^SG69-PZC<I(R/2IK/4+748'FL+F
MWN88G>-Y(9`ZJZ$AU)'&0001V((-?-/[-[?\*XT_P/G,7AWXDZ1#R>4M]9AC
MQ_P'SXAZ\O%[U/IL9U[0/#_@^ZDFBTCQ7\0M?35?)<H;BW@N+R<V[,.0KLBA
ML<E=P[UXQ^CGNNF_$;PIK.KG2M(\3:!>ZF"1]C@U*)Y21U`0-DFMFTU&TOYK
MF*RNK>XELY/*N4BE#F%\`['`/RM@@X/."#7(^,?A)X6\4^#YM&.D:=IZ0PDZ
M?<6=ND+Z?*H_=RQ,N"I4@'@C..>*\K^!_BB\7QEX;U+66;;\4_"L-Q+*W_+7
M5;!1'*P'0>9`5?C^Y0!]`OJ5G'J$5A)=6R7T\;2Q6K2J)712`6"YR5!(&1QD
M@5BR?$KPC%K(TB7Q3X=352_E_8FU.$3;LXV[-V<Y[=:\*\::M<^(?$'C7Q!I
MUS/:QWFLZ9X!TZ^@?8]K`URGV^1#V8O*8PPZ&,>E>W-\*/!A\+_\(X?#.C'1
M?*\LVAM5QC&,[OO;^^_.[/.<T`=/<3Q6D#S7<D<,,2EGDD;:J@=22>U8>C?$
M'PMXBOFLM`\2:#J5ZO6WM-1BFD]_E5B:\(\((?'NI^$O`7B^>75=$\/SZX;I
M+H9&K?V?>);6BR_WU59=Q!R&903G%>^1Z)X;T.]T^2/3]$L+T%H-/9;>**0$
MH24BX!^XK9"]@>PH`JW7Q,\'V5U+;7GBOPU#<0.8Y8I-6@5D<'!5@6X((P0:
MUQKNFMJW]E)J%BVIB'S_`+$+A?.\O^_Y>=VWWQBO$/A=XETFUM=8M+[P;KVJ
M3GQ9K"M?VWA\W,)W:A-_RUQT7.#Z8/I6?\1]&O8/BYXM\9>&(VFUWP+IFC7\
M4"#FZM&^V"[MO^!Q98?[4:4`?0-UJ-J+M;$W-O\`;6B\X6_FKYGE@XW[<YVY
M(&<8S3:\RM=7M/$'QVT74](G6YL-1\`O<VTR])(WO(RI_(BO3:`"BBB@`'6F
MM]XTX=::WWC0`E!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>["F2
M_<;_`'33Z9,0L3LQP%4Y-,F6QQS4E*:2MUL>.]PHHHH$%%%%`!1110`4444`
M%%%%`!1110`9Q1DT44`2W/B^[\.67FH!<P(Z@Q2$_=)&<'M71^'?&>F^)$Q9
MRF.XQEK>7`8?3L1]*\^\6?\`($E_WT_]"%<-&[1.KQLR.IRK*<$'U%:*C&<;
MF,LRJX>KR[KL?4%F<J_L16A'`TG^R/4UP/P6UV]U^UU-=6F-Q]C,2Q,X&0&W
MYR>_0=:]*["N"<>631]/AJ\:U)5([,9'"D62!DGN:?114FX4444`6+'_`(^X
MO]ZMZL&Q_P"/N+_>K>H`P]3_`./Q_H/Y55JUJ?\`Q^/]!_*JM`!1110`4444
M`%5=5U6VT6RDN]0D\N&/J0,DGL`.YJV.M<3\7?\`D6(O^OU/_07JHJ[2,,34
M=.C*:W1R_B7XHWVIEX-'#6%L<C?NS*X^O1?P_.N(8EV+.<L3DD\DTE%=ZBH[
M'R%7$5*KO-W"BBBF8',ZG/)::L\MK(\4B$%61L$<"NK\/_$N2,+!KR-*N?\`
MCXC'('^TO?\`#\JY#6_^0E+]1_Z"*HCK6W+&4=3&%>I2DW%GT#;SI<PI+`P>
M.10R..C`C(J2LSP;;2OX:T[Y=H-NN"W&:VS8R8RNT^V:X)*SL?2TTY13MN5Z
M*4JR$B0%3GO24AO3<****`$90PP<54FLN\9'TJY10!D$%3A@0?>DK4>!9!AN
M:J2V;+DIR/2@"M12D8-)0`4444`%%%%`!113D1I&PBD_TH`;4L<#2'Y>GK5F
M"R`YD.3Z5:`P.*`.@\$6RI#=MU(9>OT-=0.U<[X-_P!3>?[Z?UKHSUK&:]X]
M;#?PD0WMI!J-I/:WL2S6US&T<T3C*R(PP5/L037Q?KW["GB<ZW>_\(SK/AY=
M),[&R%Y<3B98B<JK@1$;@"!D$YQ7VK171AL95P]^3J>;G&08'->3ZU%OEO:S
MMN?G%\9_"-_\)+/2/`]XJLP3^U+^\BSY5].^Z-=A(!*1HI49`.YY#C#"O._#
MVO7OA;7+'5M&E\J]T^9986QD9!Z$=U(R".X)%?H9^T%\"X_C7H5A#:74.FZK
MI=P7M[N2,NIC<`21L!S@X4@]BN.YKR;X??L23^'?&.EZGXLUO3=4TW3YO/DL
MXK=U,[+RBG=QMW;21W`QWKV\/F5'V%ZCUZKN?EN:\&YDLSY<+!NGIRRNO=6F
M]]=#D+[]C'Q-XFN/[8\-76A:/I>JQQWEOIVHSSK-9"1`[0.%B8?(Q9.O(4$\
MU]!?L\?`\_!KPA>6^IS6EWKFJRE[RXMLF,(N1&BEE!*@$MT!RY]J]<Z#`&`*
M2O&KX^O6AR2>A^CY;PIEN`Q'UFE%\_=O37=I=#RFQ^#-Q<?`+2_`NLW-O#K.
ME6$0M+^U9BMK?0MOAF1BH;"R`=AD;AWJEH_P6UR7X=65AK.JV&F^,--\0W6O
M6>H::'GMX;F6>63;M<(SQLLS(R\<'J<<^QT5QGTAYGJVE_$_Q7I,^BZE_P`(
MCX<AO(C!>ZMIM_<74XC(PYMX7AC5'(S@L[;<YPV!3_'/PLN9O!WA:R^&C6%A
MJ_@:[M9]#^VLRQ%(U\IX9&56;:\3,#@')`KTFB@#S'1O@G!!\$;;P+JU](+S
MR1+<:G;/N=;_`,WSS<HQ`)(G^8$X)``/>I5?XLC3_L+0>`A>*OE_VT+RY8$=
M/-^R>2/GQSL\X+N[XKTFB@#RNZ^"<VD^'_"__""ZN;7Q-X1>XEM=1U!&F34&
MN#NNDN0#G;*YWG:<JP!7CBGW'ASQYXI\4^$+WQ;8^%-/M?#.J/>S2Z?JL]P]
MPS6TT&U(WMT"C,V>7.,=Z]1HH`\M\):!X^\$VFIV%AIO@N^L[C6;^^AFFUNY
MA?9<7,DP#(+1AD!\'YCTZ]ZZC2/"MY8?$CQ/X@N'MC9ZU8:=;P(K$NKVYN-^
MX%0,?OEQ@GOP*ZJB@#Q_X:_!G5_`'Q*O]0-WIDOA*WL+BST*UC9_M-M%/<+<
M>4X*A=B/YBJ0Q.-N:];D@S_J_P`JEHH`I$%3AA@T5=*AAAA5>2W9>5Y7U-`$
M0ZTUOO&GXP:8WWC0`E!Z44'I0!AZC_Q^2?A_(56J76+B.VN9&F8*!C^0KG+W
M77ERMH#&O]]NI_PK=1;2/.J58P;N:MYJ$-DO[QLOV0=36#?ZK+>`J/W<1_A7
MO]35-B6R222>22<YIM:*"1P5,0Y:=`HHHJC!NX4444""BBB@`HHHH`****`"
MBBB@`HHHH`****`,;Q;_`,@27_?3_P!"%<*.E=UXM_Y`DO\`OI_Z$*X4=*ZJ
M7PGD8W^+\O\`,]D_9]Y@UW_>M_\`VI7K/:O)?V??]1KO^];_`/M2O6NU>=7_
M`(C/KLJ_W2'S_,****Q/1"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;U`&'J?\`
MQ^/]!_*JM6M3_P"/Q_H/Y55H`****`"BBB@!1UKB?B[_`,BQ%_U^I_Z"]=L.
MM<3\73_Q3,7_`%^I_P"@O5T_B1RX[_=I^AX_1117H'Q@44^*&2XD"0J78]A6
M_I_AI0`^H$,?^>:GC\:3:1M2H3J/1'G]SI-SJVJS"SC+*&`9SPJ\#J:Z32?"
M-M8;9+K_`$F=>02/E7Z"NCNXTBF98E5%'0+P!Q_]:HAT-)U&]C>GA80=WJSM
M=*&-+M<8`"<`=JM56TO_`)!=M_N59KD;N?14_@0UXDE3;(`:IRV#1_ZK#`]N
MXJ]0#BBX3IJ1DY]>"*,UI36T=P/G^5O[PJA-:O">F5]157.65)IC**0$'H:6
M@R"BBB@"*6V249.0?451E@:(\\CU`K3I"@/6@#(HJ_+9J^=GRD56-K("1M)^
M@H`AI5&XX'6IX[-V^\"H_6KD4"Q#Y<Y]:`*L5D>LGY5;2%4&$&!3Z*`"BBB@
M#IO!O^IO/]]/ZUT9ZUSG@W_57G^^G]:Z,]:RGJSU\,OW*$HI<48J#8,=?;FD
M]?;K[50U_2;77-%N['4K:*\@FC),,@R&8<KQZ@@'->=_\(?J>G_!CP]IGAVV
M_L_6Q/HD]X#$6*2I<VQN))%5U+X57+#<,A3SSP`>J`%L8YR,C%)7DVI>'_%+
M^!?BO:Z@_P!NU;5&N#ILEG`\"SYTRVC3RD,CL/WBLOWN64GC-=OX!L$TWPW#
M;QV\-LR2.76'3)-/0L3G*PNS,.W))R030!T8&3@=?2C!':N$D\*WUS\89];D
MCLO[-M=*LXX'N+1I)#+NN]_DR"0",@-'NRC9!'3BLF?3M;/B;^SDL=3VCQ?'
MJHO,?Z.UDL"Y/F9P/G!3R_O9.=NWYJ`6IZA2XYQW%</<>";1_BM::R-,B:)=
M,FDDN]O'VL2Q>6W^_LWX/ID9[5D7EIK`\1W^EQ:9J;+>^*K+48+P+_HZV4<-
MOYF9"<#YX9%\O[Q+`X(;-`'IXY&1TH"E@"O.>F*\D\0>$-=G^*T&MVUNO]EQ
M7]BLDT43?:A&(Y`Q1]^/*WF-9$*G*L2#\HK7@T2X7XR7VHWMK'):O!"MG,^E
MRRL#Y3!RMP'V1C+-E2A))Z\T6`]$`)Z4F<G`ZUS?Q%LM1U#P=?0:"+F2Y=X&
MD@M9O)FN+=9T:>*-]R[7>$2H#N'+#D=1B>`M)>UU_6Y]$TR^T7PU/96RV]E=
M*T&^[4R^=*D)YC!5HE)P-[*6`XW,`=^.1D<BBN'^"_A2]\(_#W2;77([*+4I
M+.W>Z6WM&@82^2@82YD??(&#9?(!/85W-`"444N*%J`E%%%`#3&K9XP3WJI(
MC*YSS]*NU#)]YOK0!5Z].M.$18?,.#4H4#H!3AUH`\V\8$_V_<J22%V8!/3Y
M!6+6SXP!'B&[S_L?^@+6-79'8^=Q'\67J%%%%,Q"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`QO%O\`R!)?]]/_`$(5PHZ5W7BW_D"2_P"^G_H0
MKA1TKJI?">1C?XOR_P`SV/\`9]_U&N_[UO\`^U*]:[5Y-^S^I6VUMB"%9X0#
MC@D!^/UKUGM7G5_XC/KLJ_W2'S_,****Q/1"BBB@"Q8_\?<7^]6]6#8_\?<7
M^]6]0!AZG_Q^/]!_*JM6M3_X_'^@_E56@`HHHH`****`"N:^(6AW.O\`A\PZ
M<HDGAF658^A<`$$#WYKI:1G"''4]Q33L[F=6FJD'![,^;IH)+>=H9XWCF4X:
M-E(8'TQ6MI_AV6?Y[L^2G]TCYC_A7L^J:1:ZLX>ZA1I$4A)0,,H]`:Y?4_#5
MQ8C?#F>(=UZK]1_A74JZ:MU/"EE7LGS/5&!;6<-I'LMD6,'J1U/XU/1VS2JI
M=@J`DGH!2UO=EI):(R;[FX;\*9;V\ES)Y<",[GL.WU]*WE\-22W)>_)B3@[`
M/F/^%;-O:Q6D02W144>G]30YHJ&&<G>6@EG";:SAB<@M&N&QZU+1161Z$596
M"BBB@84`X_&BB@"O+9I)EH\(W\ZIRQ/`V)!QZXXK4H8!EPP!![$9JDS&I14M
M49`8'I2U:FL!DFW/_`355_D;:X(;T(IG+*$HO4****"`HHHH&%%%%`!1110`
M4444`9^O?%C2OA=I\?\`:-MJ&I:EJ]PL&FZ9IT/FW%VXZA5XSC*_F.#72_#7
MXBR^/X-0^W^&O$'AF[TV14EAU:W\OS"P)!1OX@`.>.,CK7G?C7P1XEU37/#7
MB_X=Q6=_K'@^ZG)TV[E$2W<5Q&$<*YX5@JD<D?>SG(P?1OAWK?C776U"?X@^
M'=.\-VVZ-=/M8=1%U-C!WF5E^3&=N,$'J".`3K4A#V*DK7]=5KV,,'7Q+QKI
MU&U!/1*%XM<M[N=M'S75KKIIK<R]7^-VC:-\6=.\!SV]T]]?QJ3=KM$,$CJ[
M)$V3G<P08_WAZ&M#XN_%*R^$/A,:]JUG=7UL;N.W,=L5#98$@_,<8^6O!]>^
M!7Q'U^3Q'XRANK>QURX\10ZE8:%)%"\D@MF*VQ^T^9A=L4C_`"]#CZ5ZE^T/
MX/U[XC_#;3;/P_IHEU`ZI:W5Q:2SQCRD56W@LS;3@D#@G-5*CAU.FD].IST\
M?FD\-BG*DU)7=/W>CO96UNU;5/77;8Z/1?BWI?B+QS8>'=&AGN%U/P\NN6]^
MK+Y1A:0QA",[@V1GVJA\1?C79^!==M=`TS1-:\4^(KN`W']FZ3!YCP0Y(\R0
M_P`()'OVSC(SQ/PK^"&L_#?X[:C?6R^=X-31YH-(E,RDVJRSK-]FVYW#:YEP
M<8((.<G`T_&WA#QCX1^+LGCWX<Z3:>)8=6TM=/U'3)+Q;26,JPVR([_+MPB\
M=<YXYR!TL.JMD[JW>UWYOH7]<S26!<YP<9\]G:-VH]TOM:[/71WUL>D>#/&/
M_"8>%H]9?2-6T5B9%DL=3M_*G1D)#9&>F0<'O7$_##X]O\4]0LAIW@[Q-9:7
M>K*4U:YB4VH*9!&\'J64K]:[+P;=>)M7\*-+X]TW3]*U><R[;.RN?.6*,D[%
M9NF\`X."1D9XS@>'_LV?#+Q+\--3L(?$7@.:TN989X;W7?\`A(TE18RQD4"U
M5B,DJBY'/?N:B%.DX5&]UMK_`,'7\2Z^*QL<3A(POR23YGRZ[QM=<KY;ZZ/E
M]3T3XE?'BW^'/BR+04\-:YK]VVE_VE)_9JH_EP!W5B02#@;"2>G-=UX-\66'
MCKPOIVO:$TC6&IPB2+S``Z\D%6`)`(((/)Y'>O%OC/\`!77?B5\4C>Z;/=Z;
MIO\`PB,EG'?V]ZL.;OS9&6*1<[FC8.`P`P0>M>H?![3;_1?AKH.FZ]I$6AW^
MG6JVTUI%,LJY3C>&4D'=][KG).<]:*U.BJ,91^+J:9?B,QEF=:%>+]EKRZ66
MC75+\]^FS+?Q!\977@C1(]0T_P`/ZSXD=[@1/:Z7$'DC4JS&1A_=&T#_`(%7
M,_"7XV-\67#V/A77M+TQ[9YH=4NT4V\S)($,:L.K9+<?[)KT>[C:6TG2,?-)
M&RCG')'_`-:O/?V=O!VK>!/A!HFB>*;;['J-HUQYL/F+)LW3R.OS*2#PP/7O
M6<73]B[KWK]_T.NJL8\QA&,W[)Q;:LK735E>U]4V_D6X?BY937WCZU6PNP_@
M"!9;LDKBY#0O*/+YXX0CGN:T=(^(MKK/PQ3QK#:7,=F=*DU'[,[+YFQ$+%<C
MC)"D9S7C?B#]G>?Q?XQ^*FKZ[I]V9-0AC;PT\&I>4MQ*+=E.Y4<<;P@Q(!P3
M[UZ%X5\&:OIW[.R>&+RUVZX/#5Q9_9A*K?OGC=57<#MZD=\5M4IT%%.+UTO]
MVO7N<&"Q69RK5(UH6BE.SMNU)J/16TV6MUJ/^%GQFE^*-PAM_"/B/1].FM3<
M6^IWT:BWGPRJ$5AU)R3_`,!-9?Q`_:+M/`7B_4]#?PQX@U?^Q;.*\O[JP1'2
M"!@#O8$Y`&>2<"N>_9G\!Z]\.I?L6N^")=$DGLMM]K!\1)=I<.C955MU)\O.
MYNAQQ61\8/@)XG^('Q%\9ZII;W=C;76@PIIDL-^D4=]/'LW6\J[@Q5@&`)PN
M<$GC%:JCAO;R3:Y>FOGY,X:N,SC^R:52G%NLWJN76W*W:SC'2Z2O;RNV?0^@
MZY:>)-!L=8TMRUEJ5K'<P/(NT^6ZA@2.QP:XGX1?''1?C#-K4>@VUS:G1YE7
M-PR_Z1&Q8+(F#T^1LCMWJ'6+/Q*_P%ET[P]X>&G^)'T5;"+28;B)%M&($1V/
MOV[53<ZG=G`&>>*X7X:?!CQC\*/B-X>O?MUIK^CSZ*VE:B]O:1V9L4CP\1*^
M83,2Y(W@;L9S6,:5+DFVU?6VO;_,]&KC<?'$X90IMP:7.U'K+1;ZJSU:MHM[
M'9_$KX[P?#SQ8F@1>&]>U^\.E'4Y#ID:OY<`=U8D9S@;,D^];<GQ5L;GX4GQ
M[X?L;W5M-%H;K[-"56;8I(D&"<93#9&?X3BN#^)OP6U/XB_&ZVU!KO6-)\.#
MPP;*?4-)OXX)6F\Z0F`@[CL9'Y^7!XKUSPKX3T[P;X8L=`T.'9IUA`8HD<[B
MP))8MZEB23ZDFE46'C3A;?J:8669UL57532GJHMI7OI9K2[6^][]#D?"GQNT
MKQQXML-$\*V=Y?+<Z-'JEU>J5$5BL@^6*3G/F$XX]_8UZ,>O'2O(_P!G?X93
M_#:P\5Q:CI<.FR7_`(AGDL_+E20O9*%$`RI.`,O@'D;CQS7K=8XA4U.U/8Z\
MGGBYX6-3%?&^EK6\N_GKW"H7^^WUJ:H7^^WUK$]0;2TE%`')^-="DN"+ZT4N
M47;*H&3@="*XG\#7L58>L>$[35-SQ@6UP?XX^C?45M3J=&>=B<$Y-S@><XQ1
M6EJN@WFD,?M49:/M*@RI_'M^-9P&:W33V/*E"479JPE%!&**"0HHHH`****`
M"BBB@`HHHH`****`"C&:,5>L=(GOB"B^7'_?8<'Z4-V*C!MV*./4@'ZT$8-=
MC8Z5!8K\J[Y"/F=N_P#A2W>EV]ZI$B`,>CJ,$5G[17.KZG*V^IYKXMXT67/]
M]/\`T(5Q=C87&I7<5K80R7%Q,VU(XUR6->T7'PWEUP?9KBZ%O;,RL9`F7(!Y
M`!XS[UV_ASPEI?A6W\O1[98V8?O)F^:1S[M_3I6T<1&,+'$\IJUZW-+2/];%
M7P%X7_X1+P[!:2$-<N?-N&7H7('`]@!BNAI:2N&3;=V?34Z<:<%".R"BBBD6
M%%%%`%BQ_P"/N+_>K>K!L?\`C[B_WJWJ`,/4_P#C\?Z#^55:M:G_`,?C_0?R
MJK0`444O\J`$H9@HY/X4QI>H`_&HCR<GDT`/9R3P<"F444`%'7KVHHH`R]1\
M.VNH-OP89/[R=_J*FT[1[;3`#"FZ0=9&.6/^%7J*?.TB%2@G>VI@:IQ>R@>H
M_D*J5;U7_C^E^H_D*J5HC"6X4444""BBB@`HHHH`****`"DDC25<2<^_>EHI
MW$TFK,HRV+)EHLNH[>E5\_7BM8$BHYK>.<?,"&]133.>I1[&;FBGRV[0.`W(
M/1J93.>2LPHHHH$%%%%`!11FBBP'3>#<>5>9_OI_6NCKG/!O^IO/]]/ZUT9Z
MUE4W/6PW\)!DX^M`)!X.*2BH-P[8XI<GVI**`%SD\_K1T&,"DHH`7<:"Q/4D
MTE%`!2YI**`#Z@?E2]1_/WI**`%SQU/YT9)__7244`*"1CMCICM1DXZGFDHH
M`7/K2444`+G-)12T`%5W/SM]:KZMKMEHD>Z^F4-_#$OS.WX?XUS4_B275HR\
M"F"%R1MW98@$CDU:@VKF4Z].#LWJ;E]K,%H2F?,D[A3T^M4U\3#/S0MM]G&?
MY5@YH!Q5\B.66(FWH=E::A!>)F%_F[J>"*L5PZ2-&P:,E6'0@]*V+/Q"R@+>
M@D=G7K^(J7#L;0Q">C-YXTD0I(JLK=01D&N8UCP5%-NETQA"YY\MLE3]/3^5
M=+!/'<1AH'$BGN*EJ5)Q-9TX5%JCR.]LI[";RKN-HW'KW^GK4!&*];O+&#4(
M3%=QI(A[,.GT/45QVL^"I+?=)I3&:,G_`%3??'T]:WA4ON>57P4H*\=4<K13
MI(FB<I*I1UZJPP132,&M#A:L%%%%`@HHHH`***?%$\T@2)2S-T`%#=AI7&XJ
M:ULIKQ]L"%O4]A6Q8>'#Q)?G'I&I_F:W(XTA39$JH@_A48%0YHZZ>$;^(R[#
M0(8,/<_OG[`_='X=ZUJ='$TIP@)J_!IZJ`9AN;L,\"L92OK<]&E225DBI!:O
M<'Y>%'<U?@LTA&2-S>IJP!M&!Q14.3.B,$@QZ_SJ6.X9.#\R^E144BR^D@D^
MZ1GTI:H`D=#CZ5-'<G@.,CUH`LT4`AAE2#]**`"BBB@"Q8_\?<7^]6]6#8_\
M?<7^]6]0!AZG_P`?C_0?RJK5K4_^/Q_H/Y55H`*;*2%&/XJ=3)ONK^-`$5%%
M%`!1110`4444`%%%%`&#JH(O7)_BP1^0JG70WUDMW%\IV2*/E/;\:PY[=[=L
M2*1Z'L?H:TCL<THM,BHHHIDA1110`4444`%%%%`!1110`4444`-F031,OJ.*
MREX'-;"]:QT^Z/I5(Y*\4FA:***I;F`R:9($+RL%11DL2`!7*:SXZCBW1:0J
MROT,K_='T'>H?B"[JUH@=MC%SM[9&T5QW2NFG25KGGXC$SC)QB='IOC>\MY?
M^)A_I,1.3D`,OTQ7::;K-KJL>^SD#$#YE)PR_A7E%:_A[2[BXU"UD0F&/S5_
M>=\9Z"B=-:F>'Q%1.VY[OX.B86MQ(1A9'&W\.O\`.N@-16UO':P)%`H5$&`!
M4E>?)W9]=3AR040HHHJ2PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*4
M]*1B%&7(4`9))KD];\?VUGNBTD+<S=/,S\B_X_YYJE%O8RJUHTHWDSI[N\@L
M(&FO94AC7J6.*XC6_B!+*Q@T)"`>/.<98_1>U<KJ.I7.JW!FOI6D<]!T`]@.
M@K7\'(IFN6*C>H7:WIG.:W4%"-V>;+&3K5%"&B_$;9^&[B_D\_5WD0.<X9LN
MWU]*Z--'@%LB6X,6T8'.?SJ7-68ON`5+DV=5*A3@N]_O,.XM)+8_O%^7LPZ&
MH:Z1U#(P.""*YS&,^QH1G5I\K$H!Q113,R6WNY;5]T#E3W]#]:WK#Q!'*`EW
MB)^@/8USE`XJ7%,N%64-CNE(=05((/0@TM<?9:E-9']TP*=T8<&N@T_5X+T!
M0?+D/\#\?D>]9N+1VPK1EOH-U70K35T/VF/$F.)$&&'^-<3J_A2[TS=)&#<6
MX_C1>0/<5Z1T-)BG&;3,ZV%IU-]SQ['I2$8KT36/"-KJ6Z2#;;3DYW*ORL?<
M#^8KBM3T2ZTB0+=Q_(?NR+]TUO&I%GDUL+4IO78H44459S`.M=%X9A3R9I<#
M>6VY]L9_K7.CK78^&-,F6T)G1HED?<N\8)&!SBHJ-)'7A(-U$70"S849/H*M
MPV!)!F./]FKL5ND(&Q0#W..34E<[EV/8A3MN-1%1<*`!3J**DU"BBB@`HHHH
M`****`)K8D2X[$5:JI;_`.M'T-6Z`"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;
MU`%&[@C,N60$D<G)J'[/%_SS'YG_`!HHI`'V>+_GF/S/^-(;6%NL8X_VC_C1
M10`GV.#_`)YC_OH_XT?8X/\`GF/^^C_C110`?8X/^>8_[Z/^-'V.#_GF/^^C
M_C110`?8X/\`GF/^^C_C1]C@_P">8_[Z/^-%%`!]C@_YYC_OH_XT?8X/^>8_
M[Z/^-%%`!]C@_P">0_[Z/^-,DTZVE4K)"K`]BQ_QHHHNP:ON5_\`A'M._P"?
M4?\`?Q_\:/\`A'M._P"?4?\`?Q_\:**+L7*NP?\`"/:=_P`^H_[^/_C1_P`(
M]IW_`#ZC_OX_^-%%%V+E78/^$>T[_GU'_?Q_\:/^$>T[_GU'_?Q_\:**+L.5
M=@_X1[3O^?4?]_'_`,:='X=TUG`-J,'_`*:/_C11338<J[%G_A%=+_Y]?_(K
M_P"-'_"*Z7_SZ_\`D5_\:**=V'*NP?\`"*Z7_P`^O_D5_P#&C_A%=+_Y]?\`
MR*_^-%%%V'*NP?\`"*Z7_P`^O_D5_P#&H1X)T4=+/_R-)_\`%444KL3IP>Z#
M_A"M&_Y\_P#R,_\`\51_PA6C?\^?_D:3_P"*HHH4GW%[&G_*ON*.H_##PSJQ
M0ZAIOFF/.W_295QGKT8>E4_^%,>#O^@/_P"3D_\`\7115>TFMF2\-1;NX+[D
M/C^#OA")U=-'&5Z9NYB/R+U>C^'/AV)U:/3\,A!4_:)>,?\``J**/:3?4%AJ
M*V@ON1N?V=;_`///_P`>/^-']G6__//_`,>/^-%%2;!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>
M/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`%/4?#&G:M$([^!Y(QSL$[J#]0&&?QK
M._X5MX<_Z!W_`),R_P#Q5%%--K8SE2IRWB@_X5MX<_Z!W_DS+_\`%58L_`^B
M:>6-I9>67QN_?R'./JU%%/FEW!4::=U%?<6O^$9TW_GV_P#(K_XTJ^'-.3.V
MWQG_`*:-_C112NR^5=AW_"/Z>1_Q[_\`D1O\:K?\(;H__/H?^_TG_P`5111=
MB<4]T)_PAFC_`//H?^_S_P#Q5'_"&:/_`,^A_P"_S_\`Q5%%',^Y/)'L'_"&
M:/\`\^A_[_/_`/%4?\(9H_\`SZ'_`+_/_P#%444<S[AR1[!_PANC_P#/H?\`
MO\__`,52CP=I`.1:$$?]-Y/_`(JBBB[*4(]B['HUG$@1(CM7IF1C_,T[^RK7
M_GE_X^W^-%%(H/[*M?\`GE_X^?\`&F2Z+931LDL"NC#!!)(/ZT44`9)^'?AX
MG/\`9_Y7$O\`\51_PKKP]_T#S_X$R_\`Q5%%5S2[F7L*7\J^XEM?`>A6<PE@
ML%$B]"TKMC\V-:7]C6?_`#Q_\?;_`!HHI-M[E1IPCLK!_8UG_P`\?_'V_P`:
M/[&L_P#GC_X^W^-%%(L/[&L_^>/_`(^W^-']C6?_`#Q_\?;_`!HHH`/[&L_^
M>/\`X^W^-']C6?\`SQ_\?;_&BB@`_L:S_P">/_C[?XT?V-9_\\?_`!]O\:**
M`#^QK/\`YX_^/M_C1_8UG_SQ_P#'V_QHHH`5=)M$.5BP?]]O\:?_`&=;_P#/
M/_QX_P"-%%`!_9UO_P`\_P#QX_XT?V=;_P#//_QX_P"-%%`"QV$$3AT3##H=
(QJQ110!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
